title: The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.
abstract: The safety of blood transfusion is still threatened by contamination of blood products with a variety of pathogens such as viruses, bacteria and parasites. A novel pathogen reduction process for platelets and plasma products, the Mirasol PRT system, has been developed and is under clinical evaluation for its efficacy and safety. The Mirasol PRT process is based on riboflavin photochemistry. This manuscript reviews current progress and future trends.
authors.affiliation: Navigant Biotechnologies Inc, Lakewood, CO 80215, USA. ray.goodrich@navigantbiotech.com
authors.forename: Raymond P
authors.initials: RP
authors.lastname: Goodrich
authors.forename: Richard A
authors.initials: RA
authors.lastname: Edrich
authors.forename: Junzhi
authors.initials: J
authors.lastname: Li
authors.forename: Jerard
authors.initials: J
authors.lastname: Seghatchian
mesh_terms: D016913:Blood Component Transfusion / Q000379:methods / Q000639:trends; D001793:Blood Preservation / Q000379:methods / Q000639:trends; D003140:Communicable Disease Control / Q000379:methods / Q000639:trends; D006801:Humans; D010777:Photochemistry / Q000379:methods / Q000639:trends; D010983:Plateletpheresis / Q000379:methods / Q000639:trends; D012256:Riboflavin / Q000737:chemistry / Q000494:pharmacology
chemical_list: D012256:Riboflavin